Exendin PET/CT for Imaging of Paragangliomas

NCT05418907 · Unknown status

Last updated 2026-05-28

This clinical trial is testing a new imaging method using 68Ga-exendin-4 PET/CT to detect paragangliomas in people with this condition.

Status Unknown status The sponsor has not confirmed the status recently.

Type Observational

Participants 10 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2022-06 · est. completion 2024-12

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT05418907 ↗

Description as written by the study sponsor.

Functional imaging of paragangliomas (PGLs) is not unequivocal. Existing functional imaging modalities show good but variable results in PGLs, warranting the search for additional molecular imaging targets. Investigators aim to evaluate the glucagon-like peptide 1 receptor (GLP-1R) as a novel target for molecular imaging of PGLs. For this purpose investigators will use the tracer 68Ga-NODAGA-exendin 4 for positron emission tomography/computed tomography (PET/CT) imaging.

Treatments tested

68Ga-NODAGA-exendin-4 PET/CT Radiation

PET/CT imaging 1 hour after injection of 100 MB 68Ga-NODAGA-exendin-4

Main thing measured	detection rate of PGL's using 68Ga-exendin-4 PET/CT
Sponsor	Radboud University Medical Center
Conditions studied	Paraganglioma
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05418907 ↗